United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 1,232 shares of the firm’s stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $133.32, for a total value of $164,250.24. Following the completion of the sale, the chief executive officer now directly owns 2,301 shares of the company’s stock, valued at approximately $306,769.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Shares of United Therapeutics Corporation (UTHR) traded down 9.51% on Friday, reaching $120.82. The company’s stock had a trading volume of 2,279,211 shares. The company has a market capitalization of $5.25 billion, a price-to-earnings ratio of 14.01 and a beta of 1.52. United Therapeutics Corporation has a 1-year low of $110.90 and a 1-year high of $169.89. The stock has a 50-day moving average price of $130.40 and a 200-day moving average price of $130.93.

United Therapeutics Corporation (NASDAQ:UTHR) last released its quarterly earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share for the quarter, missing the consensus estimate of $3.61 by $4.86. The company had revenue of $444.60 million for the quarter, compared to analysts’ expectations of $391.53 million. United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. The business’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the business posted $4.42 EPS. On average, equities research analysts forecast that United Therapeutics Corporation will post $10.09 EPS for the current year.

WARNING: “Martine A. Rothblatt Sells 1,232 Shares of United Therapeutics Corporation (UTHR) Stock” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was copied illegally and republished in violation of US & international copyright & trademark law. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/09/08/martine-a-rothblatt-sells-1232-shares-of-united-therapeutics-corporation-uthr-stock.html.

A number of equities research analysts recently commented on the company. UBS AG reaffirmed a “sell” rating and set a $106.00 target price on shares of United Therapeutics Corporation in a report on Thursday, July 6th. ValuEngine raised United Therapeutics Corporation from a “buy” rating to a “strong-buy” rating in a report on Thursday, July 13th. BidaskClub downgraded United Therapeutics Corporation from a “buy” rating to a “hold” rating in a report on Wednesday, July 19th. Jefferies Group LLC reaffirmed a “sell” rating and set a $105.00 target price on shares of United Therapeutics Corporation in a report on Friday, July 14th. Finally, Zacks Investment Research downgraded United Therapeutics Corporation from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. Six analysts have rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $134.50.

Large investors have recently made changes to their positions in the company. JPMorgan Chase & Co. grew its position in shares of United Therapeutics Corporation by 1.8% in the first quarter. JPMorgan Chase & Co. now owns 122,497 shares of the biotechnology company’s stock valued at $16,583,000 after purchasing an additional 2,223 shares during the period. Clarity Capital KCPS Ltd. purchased a new stake in shares of United Therapeutics Corporation in the first quarter valued at $230,000. Argent Capital Management LLC grew its position in shares of United Therapeutics Corporation by 2.4% in the first quarter. Argent Capital Management LLC now owns 2,530 shares of the biotechnology company’s stock valued at $343,000 after purchasing an additional 60 shares during the period. Nuveen Asset Management LLC grew its position in shares of United Therapeutics Corporation by 222.1% in the first quarter. Nuveen Asset Management LLC now owns 64,507 shares of the biotechnology company’s stock valued at $8,733,000 after purchasing an additional 44,481 shares during the period. Finally, Greylin Investment Mangement Inc. grew its position in shares of United Therapeutics Corporation by 42.3% in the second quarter. Greylin Investment Mangement Inc. now owns 2,975 shares of the biotechnology company’s stock valued at $386,000 after purchasing an additional 885 shares during the period.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Insider Buying and Selling by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.